PRQR
Income statement / Annual
Last year (2023), ProQR Therapeutics N.V.'s total revenue was $6.38 M,
an increase of 58.05% from the previous year.
In 2023, ProQR Therapeutics N.V.'s net income was -$27.54 M.
See ProQR Therapeutics N.V.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$6.38 M
|
$4.04 M
|
$1.35 M
|
$0.00
|
$1.93 M
|
$4.94 M
|
-$1.53 M
|
$2.28 M
|
$9.41 M
|
$313,000.00
|
| Cost of Revenue |
$0.00 |
$2.48 M |
$0.00 |
$2.19 M |
$116.82 M |
$983,511.00 |
$1.00 M |
$1.28 M |
$482,849.00 |
$0.00 |
| Gross Profit |
$6.38 M |
$1.56 M |
$1.35 M |
-$2.19 M |
-$114.89 M |
$3.96 M |
-$2.53 M |
$1.00 M |
$8.92 M |
$313,000.00 |
| Gross Profit Ratio |
1 |
0.39 |
1 |
0 |
-59.44 |
0.8 |
1.65 |
0.44 |
0.95 |
1 |
| Research and Development
Expenses |
$22.68 M
|
$50.87 M
|
$42.22 M
|
$38.14 M
|
$46.49 M
|
$29.51 M
|
$31.15 M
|
$31.92 M
|
$23.40 M
|
$10.27 M
|
| General & Administrative
Expenses |
$16.24 M
|
$18.65 M
|
$17.37 M
|
$13.69 M
|
$12.89 M
|
$12.54 M
|
$10.84 M
|
$9.48 M
|
$6.84 M
|
$6.51 M
|
| Selling & Marketing
Expenses |
-$841,167.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$15.39 M
|
$18.65 M
|
$17.37 M
|
$13.69 M
|
$12.89 M
|
$12.54 M
|
$10.84 M
|
$9.48 M
|
$6.84 M
|
$6.51 M
|
| Other Expenses |
$953,000.00 |
-$765,000.00 |
-$1.04 M |
$9.37 M |
$1.93 M |
$5.76 M |
$1.50 M |
$1.83 M |
$3.24 M |
$313,000.00 |
| Operating Expenses |
$38.07 M |
$68.75 M |
$58.55 M |
$51.82 M |
$59.38 M |
$42.05 M |
$41.99 M |
$41.40 M |
$30.24 M |
$16.77 M |
| Cost And Expenses |
$40.54 M |
$68.75 M |
$58.55 M |
$51.82 M |
$59.38 M |
$42.05 M |
$41.99 M |
$41.40 M |
$30.24 M |
$16.77 M |
| Interest Income |
$2.59 M |
$106,000.00 |
$5,000.00 |
$313,000.00 |
$402,000.00 |
-$792,000.00 |
-$3.18 M |
$470,000.00 |
$6.17 M |
$4.33 M |
| Interest Expense |
$1.15 M |
$5.13 M |
$3.41 M |
$2.04 M |
$1.08 M |
$810,000.00 |
$596,000.00 |
$538,000.00 |
$395,000.00 |
$265,000.00 |
| Depreciation &
Amortization |
$2.46 M
|
$2.48 M
|
$2.42 M
|
$2.19 M
|
$2.05 M
|
$983,511.00
|
$1.00 M
|
$1.28 M
|
$480,000.00
|
$126,000.00
|
| EBITDA |
-$31.69 M
|
-$59.38 M
|
-$55.38 M
|
-$49.47 M
|
-$57.33 M
|
-$41.06 M
|
-$40.93 M
|
-$40.16 M
|
-$29.76 M
|
-$16.65 M
|
| EBITDA Ratio |
-4.97 |
-14.71 |
-40.9 |
0 |
-29.66 |
-8.31 |
26.77 |
-17.6 |
-3.16 |
-53.19 |
| Operating Income Ratio
|
-5.35
|
-16.03
|
-42.24
|
0
|
-29.72
|
-7.35
|
26.49
|
-17.34
|
-2.87
|
-52.59
|
| Total Other
Income/Expenses Net |
$6.91 M
|
-$79,000.00
|
-$4.37 M
|
-$4.12 M
|
$831,000.00
|
$5.76 M
|
$1.50 M
|
$1.83 M
|
$3.24 M
|
$313,000.00
|
| Income Before Tax |
-$27.24 M |
-$64.80 M |
-$61.56 M |
-$46.49 M |
-$56.61 M |
-$37.09 M |
-$43.67 M |
-$39.10 M |
-$20.83 M |
-$12.13 M |
| Income Before Tax Ratio
|
-4.27
|
-16.05
|
-45.47
|
0
|
-29.29
|
-7.51
|
28.56
|
-17.14
|
-2.21
|
-38.74
|
| Income Tax Expense |
-$76,401.00 |
$96,000.00 |
$117,000.00 |
$124,000.00 |
$132,000.00 |
$1,000.00 |
$2,000.00 |
-$470,000.00 |
-$6.17 M |
-$4.33 M |
| Net Income |
-$27.54 M |
-$64.89 M |
-$61.68 M |
-$46.61 M |
-$56.75 M |
-$36.89 M |
-$43.64 M |
-$39.10 M |
-$20.83 M |
-$12.13 M |
| Net Income Ratio |
-4.32 |
-16.07 |
-45.55 |
0 |
-29.36 |
-7.47 |
28.54 |
-17.14 |
-2.21 |
-38.74 |
| EPS |
-0.34 |
-0.91 |
-0.96 |
-0.93 |
-1.38 |
-1.08 |
-1.72 |
-1.67 |
-0.89 |
-1.09 |
| EPS Diluted |
-0.34 |
-0.91 |
-0.96 |
-0.93 |
-1.38 |
-1.08 |
-1.72 |
-1.67 |
-0.89 |
-1.09 |
| Weighted Average Shares
Out |
$81.01 M
|
$71.64 M
|
$64.18 M
|
$50.06 M
|
$41.04 M
|
$34.05 M
|
$25.37 M
|
$23.35 M
|
$23.34 M
|
$11.08 M
|
| Weighted Average Shares
Out Diluted |
$81.01 M
|
$71.64 M
|
$64.18 M
|
$50.06 M
|
$41.04 M
|
$34.05 M
|
$25.37 M
|
$23.35 M
|
$23.34 M
|
$11.08 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
